# Electrotherapy in the management of neuropathic corneal pain: narrative review

**Authors:** A. V. Shanmathi, Mingyi Yu, Chang Liu, Isabelle Xin Yu Lee, Louis Tong, Yu-Chi Liu

PMC · DOI: 10.3389/ebm.2026.10712 · Experimental Biology and Medicine · 2026-02-06

## TL;DR

This paper reviews electrotherapy as a potential treatment for neuropathic corneal pain, a condition causing persistent eye pain and discomfort.

## Contribution

The paper provides a narrative review of electrotherapy's mechanisms and clinical potential for managing neuropathic corneal pain.

## Key findings

- Electrotherapy may modulate pain pathways and reduce hypersensitivity in neuropathic corneal pain.
- Current evidence suggests electrotherapy could promote nerve regeneration and restore corneal homeostasis.
- Standardized protocols and clinical trials are needed to optimize electrotherapy for this condition.

## Abstract

Neuropathic corneal pain (NCP) is a debilitating condition resulting from corneal nerve damage or dysfunction, leading to persistent ocular pain, discomfort and hypersensitivity. Conventional therapy with eye drops often provides inadequate relief, necessitating the need for alternative therapeutic approaches. This review explores the role of electrotherapy in managing NCP, including its mechanisms, clinical efficacy, and potential integration into multimodal treatment strategies. We examine current evidence on various electrotherapy modalities such as transcutaneous electrical nerve stimulation, neurostimulation, and microcurrent stimulation. These electrotherapies have the potential to modulate pain pathways, promote nerve regeneration, and restore corneal homeostasis. Emerging studies suggest electrotherapy may alleviate NCP by altering neural signaling and reducing hyperalgesia. Integrating electrotherapy into existing pain management strategies may enhance the outcomes for patients with refractory NCP. However, its clinical application remains limited by a lack of standardized protocols and robust clinical trials. Although electrotherapy presents a promising and non-invasive option for NCP management, further research is needed to optimize the treatment parameters and optimal duration, assess the long-term efficacy, and establish guidelines for clinical use.

## Full-text entities

- **Genes:** Piezo2 (piezo-type mechanosensitive ion channel component 2) [NCBI Gene 667742] {aka 5930434P17, 9030411M15Rik, 9430028L06Rik, Fam38b, Fam38b2}, MBP (myelin basic protein) [NCBI Gene 4155], BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, CALCA (calcitonin related polypeptide alpha) [NCBI Gene 796] {aka CALC1, CGRP, CGRP-I, CGRP-alpha, CGRP1, CT}, POMC (proopiomelanocortin) [NCBI Gene 5443] {aka ACTH, CLIP, LPH, MSH, NPP, OBAIRH}, Grin1 (glutamate receptor, ionotropic, NMDA1 (zeta 1)) [NCBI Gene 14810] {aka GluN1, GluRdelta1, GluRzeta1, M100174, NMD-R1, NMDAR1}, NEFL (neurofilament light chain) [NCBI Gene 4747] {aka CMT1F, CMT2E, CMTDIG, NF-L, NF68, NFL}, TAC1 (tachykinin precursor 1) [NCBI Gene 6863] {aka Hs.2563, NK2, NKNA, NPK, TAC2}, mucin [NCBI Gene 100508689], VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, NGF [NCBI Gene 103350089], MT2A (metallothionein 2A) [NCBI Gene 4502] {aka MT-2, MT-II, MT2}, SPRR1A (small proline rich protein 1A) [NCBI Gene 6698] {aka SPRK}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, VAMP2 (vesicle associated membrane protein 2) [NCBI Gene 6844] {aka NEDHAHM, SYB2, VAMP-2}, CKB (creatine kinase B) [NCBI Gene 1152] {aka B-CK, BCK, CKBB, CPK-B, HEL-211, HEL-S-29}, NGF (nerve growth factor) [NCBI Gene 4803] {aka Beta-NGF, HSAN5, NGFB}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, Opn4 (opsin 4 (melanopsin)) [NCBI Gene 30044] {aka 1110007J02Rik, Gm533}
- **Diseases:** chronic ocular pain (MESH:D059350), bleeding (MESH:D006470), depression (MESH:D003866), Neuropathic Corneal Pain (MESH:D009437), autoimmune diseases (MESH:D001327), lesion or (MESH:D009059), cardiac arrhythmias (MESH:D001145), dryness (MESH:D014987), trigeminal neuralgia (MESH:D014277), hypersensitivity (MESH:D004342), tenderness (MESH:D063806), epistaxis (MESH:D004844), paresthesia (MESH:D010292), fatigue (MESH:D005221), ES (MESH:D004556), hyperalgesia (MESH:D006930), migraine (MESH:D008881), corneal nerve damage or dysfunction (MESH:D065306), neurosensory abnormalities (MESH:D006319), axonal injuries (MESH:D001480), Tissue damage (MESH:D017695), neuropathy (MESH:D009422), epileptic (MESH:D004827), inflammation (MESH:D007249), nerve dysfunction (MESH:D005155), ocular trauma (MESH:D014947), herpes simplex keratitis (MESH:D016849), Y-CL (MESH:D002971), photophobia (MESH:D020795), nerve damage (MESH:D000080902), Corneal Neuropathy (MESH:D003316), radiation keratopathy (MESH:C562399), peripheral nerve injury (MESH:D059348), Corneal Pain (MESH:D010146), SLK (MESH:D006259), sleep disturbances (MESH:D012893), disease of the somatosensory nervous system (MESH:D020886), cancer (MESH:D009369), laser-assisted in situ keratomileusis (MESH:D002278), polyneuropathy (MESH:D011115), diabetes (MESH:D003920), fibromyalgia (MESH:D005356), cardiovascular disease (MESH:D002318), infected (MESH:D007239), diabetic neuropathy (MESH:D003929), Ocular Surface Disease (MESH:D010534), anxiety (MESH:D001007), trigeminal nerve injury (MESH:D061221), dizziness (MESH:D004244), neuroinflammation (MESH:D000090862), edema (MESH:D004487), Ocular Pain (MESH:D058447), DED (MESH:D015352)
- **Chemicals:** steroids (MESH:D013256), lipid (MESH:D008055), glutamate (MESH:D018698), gabapentin (MESH:D000077206), GABA (MESH:D005680), norepinephrine (MESH:D009638), chloride (MESH:D002712), calcium (MESH:D002118), serotonin (MESH:D012701), pregabalin (MESH:D000069583), adenosine (MESH:D000241), EXNS (-), cyclosporines (MESH:D003524), duloxetine (MESH:D000068736), prostaglandins (MESH:D011453), leukotrienes (MESH:D015289), naltrexone (MESH:D009271)
- **Species:** Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** rs140293404

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12920253/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12920253/full.md

## References

93 references — full list in the complete paper: https://tomesphere.com/paper/PMC12920253/full.md

---
Source: https://tomesphere.com/paper/PMC12920253